Severe Hypertriglyceridemia Market is Expected to Increase with a CAGR of 8.1% During the Study Period (2019-32)

The overall Severe Hypertriglyceridemia market is expected to increase due to the rising prevalent cases over the globe and thus the surge in treatment options. In addition, the expected launch of emerging therapies will boost the Severe Hypertriglyceridemia market in the forecasted period (2022-2032).

DelveInsight's Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, Severe Hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key takeaways from the Severe Hypertriglyceridemia Market Research Report

• As per DelveInsight analysis, the Severe Hypertriglyceridemia market size in the 7MM was found to be approximately USD 3,060 million in 2021.
• As per the estimates, the total number of Hypertriglyceridemia prevalent cases associated in 7MM countries was approximately 154 million in 2021, out of which approximately 3 million cases were diagnosed prevalent cases of Severe Hypertriglyceridemia.
• Leading Severe Hypertriglyceridemia companies Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others are working to develop a new medication for Severe Hypertriglyceridemia which can be available in the Severe Hypertriglyceridemia market in the upcoming years.
• The Severe Hypertriglyceridemia therapies in the pipeline include Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others.

Discover more about therapies set to grab major Severe Hypertriglyceridemia market share @ https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Overview

High amounts of triglycerides are a defining feature of the disease Hypertriglyceridemia. Triglyceride levels in patients with Severe Hypertriglyceridemia (SHTG) are more than three times normal. It causes a variety of dangerous conditions, including cardiovascular disease (CVD) and Acute Pancreatitis. High triglycerides may contribute to artery hardening or thickening (arteriosclerosis), which increases the risk of stroke, heart attack, and heart disease. Genetic problems, obesity, uncontrolled diabetes, and certain drugs can all contribute to the development of Severe Hypertriglyceridemia. Primary and secondary hypertriglyceridemia are the two broad forms of severe hypertriglyceridemia. The former is caused by other underlying diseases and secondary circumstances, whereas the latter is caused by genetic problems. Primary hypertriglyceridemia has a molecular basis in less than 5% of cases, while secondary hypertriglyceridemia has no repeatable genetic susceptibility component.

Severe Hypertriglyceridemia Epidemiology Segmentation in the 7MM
• Hypertriglyceridemia Prevalent Cases
• Hypertriglyceridemia Diagnosed Prevalent Cases
• Hypertriglyceridemia Severity-specific Diagnosed Prevalent Cases
• Hypertriglyceridemia Etiology-specific Diagnosed Prevalent Cases

Severe Hypertriglyceridemia Treatment Market

Popular Hypertriglyceridemia treatment guidelines, such as the AHA/ACC lipid treatment guidelines, recommend addressing and treating lifestyle factors, secondary variables such as diabetes mellitus, chronic liver or kidney disease, and/or nephrotic syndrome, hypothyroidism, and drugs that elevate triglycerides. If serum triglycerides remain elevated after adjusting these parameters, pharmaceutical therapy should be considered. The goal of pharmacological treatment is to lower triglyceride levels while also lowering the risk of pancreatitis and cardiovascular disease in people with severe hypertriglyceridemia. Most Severe Hypertriglyceridemia treatment guidelines recommend using statins, fibrates, omega-3 fatty acids, or niacin for Severe Hypertriglyceridemia treatment. These guidelines, however, are mostly based on observational studies.

Some approved drugs for the treatment of Severe Hypertriglyceridemia that have been replaced by generics include Lovaza or Omacor (Omega-3-fatty acid), Vascepa, and Crestor (rosuvastatin calcium). Epanova (Omega-3-carboxylic acid), an AstraZeneca-marketed drug, received FDA approval in 2014 for the treatment of adults with severe hypertriglyceridemia. Epanova was the first FDA-approved prescription omega-3 fatty acid supplement. Triglide (fenofibrate) by Skyepharma Ag was approved by the FDA in 2005 as a lipid-regulating medication for the treatment of hypercholesterolemia and hypertriglyceridemia. Waylivra is approved in Europe to treat adult patients with genetically proven familial chylomicronemia syndrome (FCS) who are at high risk of pancreatitis and have not responded to diet or triglyceride-lowering medication.

Severe Hypertriglyceridemia Pipeline Therapies and Key Companies
• Olezarsen: Ionis Pharmaceuticals
• Pegozafermin (BIO89-100): 89bio, Inc.
• ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
• Epeleuton (DS102): Afimmune Pharmaceutical
• NST-1024 (SEFA 1024): NorthSea Therapeutics B.V.
• Lomitapide: Amryt Pharma

Severe Hypertriglyceridemia Market Dynamics

The present unmet need of the Severe Hypertriglyceridemia market is for medications with improved safety and efficacy that give an optimal cure. The growing prevalence of primary and secondary causes, as well as the increasing number of episodes of primary and secondary causes, are anticipated to result in an increase in Severe Hypertriglyceridemia treatment choices across the globe. As a result, the Severe Hypertriglyceridemia market will experience an increase in the coming year. Furthermore, the increasing awareness and updates in diagnosis and treatment guidelines will boost the Severe Hypertriglyceridemia market.

Discover more about the future Severe Hypertriglyceridemia market share of treatment therapies and Medication for Severe Hypertriglyceridemia Treatment @ https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Hypertriglyceridemia Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• Severe Hypertriglyceridemia Companies- Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others.
• Severe Hypertriglyceridemia Pipeline Therapies- Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others
• Severe Hypertriglyceridemia Market Dynamics: Severe Hypertriglyceridemia Market Drivers and Barriers

Table of Content
1. Key Insights
2. Severe Hypertriglyceridemia Report Introduction
3. Severe Hypertriglyceridemia Market Overview at a Glance
4. Executive Summary of Severe Hypertriglyceridemia
5. Key Events
6. Disease Background and Overview
7. Severe Hypertriglyceridemia Epidemiology and Patient Population
8. Patient Journey
9. Severe Hypertriglyceridemia Marketed Drugs
10. Severe Hypertriglyceridemia Emerging Drugs
11. Severe Hypertriglyceridemia: Seven Major Market Analysis
12. KOL Views
13. Severe Hypertriglyceridemia Market Drivers
14. Severe Hypertriglyceridemia Market Barriers
15. SWOT Analysis
16. Unmet Needs
17. Reimbursement and Severe Hypertriglyceridemia Market Access
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know about more the management of Severe Hypertriglyceridemia Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.